Thermo Fisher Scientific Inc. · TMO · Next earnings

Thermo Fisher Scientific Inc. reports Wednesday, Oct 28, 2026

TMO reports before market open with consensus EPS at $6.40 and revenue at $11.95B. Last quarter: TMO Q2 2026: Revenue Up 10%, EPS Up 13% as Guidance Rises Again

Reports Before market open38 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $6.40 Calendar consensus
Consensus revenue $11.95B Calendar consensus
Report date Oct 28, 2026 Wednesday, date estimated
Session Before market open 38 days away

Where TMO left off: FY2026 Q2

Full report

TMO Q2 2026: Revenue Up 10%, EPS Up 13% as Guidance Rises Again

EPS surprise +5.4% Reported $6.03 vs $5.72
Revenue surprise +2.5% Reported $11.99B vs $11.71B
Stock move +8.7% Event window
Subsequent drift -2.2% Up to 20 sessions

Full-year 2026 revenue guidance tightened to $47.4-$48.1B (from $47.3-$48.1B), raising the floor by $0.1B. Adjusted EPS guidance raised from $24.64-$25.12 to $24.93-$25.33, a $0.29 increase at the low end and $0.21 at the high end. This marks the second consecutive quarterly guidance raise.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Integration risk from recent acquisitions (Clario, filtration & separation) if synergies materialize slower than expected
  • Potential FX headwinds reversing the current tailwind that benefited reported growth
  • Unfavorable product mix shifts that could compress margins despite revenue growth
  • Macro uncertainty and geopolitical tensions that could dampen industrial and academic demand
  • Regulatory and compliance risks inherent to life-science and diagnostic businesses

Questions analysts left open

  • Sustainability of broad-based end-market strength and whether share gains are durable
  • Guidance phasing assumptions and organic growth outlook for H2 2026
  • Visibility and performance of PPD and clinical research services
  • Chemical analysis business outlook amid commodity price volatility
  • Competitive dynamics and upcoming product launches in bioprocessing downstream

Ask FN2 about TMO next report

Transcript, numbers and history already loaded
What should I watch for in TMO's next earnings report?How did TMO guide last quarter, and is consensus above or below that?Give me the bull and bear case going into TMO earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the TMO recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent TMO quarters

All TMO earnings
+8.7%FY2026 Q2

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.